Gapping up
In reaction to strong earnings/guidance:
- NA.
M&A news:
- XRM +100.8% (to be acquired by Andritz AG for $13.50/share in cash)
- EDR +1.3% (to be acquired by Greystar Real Estate Partners for $41.50/share in cash, or approximately $4.6 bln)
Other news:
- GKOS +2.7% (receives PMA from the FDA for the iStent inject Trabecular Micro-Bypass System indicated for the reduction of intraocular pressure in adult mild-to-moderate primary open-angle glaucoma (POAG) patients undergoing concomitant cataract surgery)
- MNKD +2% (reports positive clinical data for Afrezza)
- TKC +1.6% (following Turkey elections)
- ARRY +1.3% (reports Phase 3 BEACON CRC safety lead-in of the combination of Encorafenib, Binimetinib and Cetuximab)
- NVO +1.3% (Significant blood sugar improvement with Xultophy compared to insulin glargine U-100 when used as add-on to oral diabetes medications)
- SM +0.8% (provides interim second quarter update - production exceeding expectations)
Analyst comments:
- FSLR +3.4% (upgraded to Buy from Neutral at BofA/Merrill)
- ALRM +1.8% (upgraded to Strong Buy at Raymond James)
- CIEN +1.7% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- BWA +0.8% (upgraded to Buy from Neutral at Goldman)
- NTR +0.6% (upgraded to Strong Buy from Outperform at Raymond James)
- TPR +0.6% (initiated with a Buy at Goldman and added to Conviction Buy List)
![]()